Integrated multi-omics recently pinpointed the nucleotide-metabolism enzyme Cmpk1 as a monocyte-specific target in renal ischemia-reperfusion injury, underscoring that lineage-restricted metabolic hubs can be therapeutically leveraged to tame immune-driven renal disease—a rationale readily extendable to high-SRSM ccRCC (37). The gene discussed is CMPK1; the disease is nonpapillary renal cell carcinoma.